Han Jung
Corporate Officer/Principal bei Korean Institute of Certified Public Accountants
Profil
Han Jung is currently a Member at the Korean Institute of Certified Public Accountants.
Previously, Mr. Jung worked as a Director at Glycostem Therapeutics BV.
Aktive Positionen von Han Jung
Unternehmen | Position | Beginn |
---|---|---|
Korean Institute of Certified Public Accountants | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Han Jung
Unternehmen | Position | Ende |
---|---|---|
Glycostem Therapeutics BV
Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Korean Institute of Certified Public Accountants | |
Glycostem Therapeutics BV
Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | Health Technology |